MedTrace Logo

A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older Adults

NCT06556147 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2026-05-20

No results posted yet for this study

Summary

The main purposes of this study are to assess the safety, reactogenicity and immunogenicity of 4 dose levels of the bivalent combination Respiratory Syncytial Virus (RSV) / human Metapneumovirus (hMPV) vaccine candidate VXB-241 when administered as a single-dose regimen to healthy adults 60 to 83 years of age, and to assess the impact of revaccination approximately 1 year later.

Conditions

  • Healthy Volunteers

Interventions

BIOLOGICAL

VXB-241 60 mcg (Low Dose)

VXB-241 low dose, single, IM injection.

BIOLOGICAL

VXB-241 120 mcg (Medium Dose)

VXB-241 medium dose, single, IM injection.

BIOLOGICAL

VXB-241 240 mcg (Medium-high Dose)

VXB-241 medium-high dose, single, IM injection.

BIOLOGICAL

VXB-241 480 mcg (High Dose)

VXB-241 high dose, single, IM injection.

BIOLOGICAL

VXB-241 240 mcg

VXB-241 240 mcg (RSV preF 120 mcg + hMPV preF 120 mcg) (based on 1 month post 1st IMP injection results) single, IM injection.

OTHER

Placebo

Placebo, single, IM injection.

BIOLOGICAL

Arexvy 120 mcg

Arexvy 120 mcg, single, IM injection.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
83 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-08-13
Primary Completion
2025-02-14
Completion
2027-05-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06556147 on ClinicalTrials.gov